Danve, Abhijeet http://orcid.org/0000-0002-3032-0828
Vadhariya, Aisha http://orcid.org/0000-0002-1811-5370
Lisse, Jeffrey
Cholayil, Arjun http://orcid.org/0009-0002-7353-8461
Bansal, Neha http://orcid.org/0009-0008-9446-3132
Bello, Natalia http://orcid.org/0000-0001-5042-9460
Bakewell, Catherine http://orcid.org/0000-0003-2367-0640
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 24 April 2024
Accepted: 29 July 2024
First Online: 20 August 2024
Declarations
:
: Abhijeet Danve: Research Grants, Novartis, Eli Lilly; Advisory board member, Novartis, AbbVie, UCB, Janssen, and Amgen. Aisha Vadhariya, Jeffrey Lisse, Arjun Cholayil, Neha Bansal, and Natalia Bello: Employment and stockholder, Eli Lilly and Company. Catherine Bakewell: Consulting and/or speaker honoraria, AbbVie, Janssen, Lilly, Pfizer, UCB, Sanofi, and Novartis.
: As this observational study used de-identified Merative L.P. MarketScan databases, a formal Consent to Release Information form and Ethical Review Board approval or waiver were not required. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of the country or countries where the study was conducted, as appropriate. Data accessed were compliant with the US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations.